OGEN
Price:
$0.1913
Market Cap:
$4.11M
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials rela...[Read more]
Industry
Biotechnology
IPO Date
2004-02-25
Stock Exchange
AMEX
Ticker
OGEN
According to Oragenics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.12. This represents a change of -69.06% compared to the average of -0.39 of the last 4 quarters.
The mean historical PE Ratio of Oragenics, Inc. over the last ten years is -1.83. The current -0.12 PE Ratio has changed 555.78% with respect to the historical average. Over the past ten years (40 quarters), OGEN's PE Ratio was at its highest in in the September 2024 quarter at -0.25. The PE Ratio was at its lowest in in the June 2016 quarter at -16.34.
Average
-1.83
Median
-1.27
Minimum
-4.69
Maximum
-0.23
Discovering the peaks and valleys of Oragenics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 233.59%
Maximum Annual PE Ratio = -0.23
Minimum Annual Increase = -72.06%
Minimum Annual PE Ratio = -4.69
Year | PE Ratio | Change |
---|---|---|
2024 | -0.23 | -62.26% |
2023 | -0.61 | -31.46% |
2022 | -0.89 | -72.06% |
2021 | -3.20 | 233.59% |
2020 | -0.96 | -32.40% |
2019 | -1.42 | 25.72% |
2018 | -1.13 | -34.29% |
2017 | -1.72 | -49.94% |
2016 | -3.43 | -26.86% |
2015 | -4.69 | -15.50% |
The current PE Ratio of Oragenics, Inc. (OGEN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.58
5-year avg
-1.18
10-year avg
-1.83
Oragenics, Inc.’s PE Ratio is less than Onconova Therapeutics, Inc. (-0.01), greater than Tonix Pharmaceuticals Holding Corp. (-1.34), greater than Acasti Pharma Inc. (-2.77), less than Jaguar Health, Inc. (-0.09), less than Avinger, Inc. (-0.06),
Company | PE Ratio | Market cap |
---|---|---|
-0.01 | $20.90M | |
-1.34 | $191.10M | |
-2.77 | $34.17M | |
-0.09 | $3.77M | |
-0.06 | $1.52M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oragenics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oragenics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Oragenics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Oragenics, Inc. (OGEN)?
What is the highest PE Ratio for Oragenics, Inc. (OGEN)?
What is the 3-year average PE Ratio for Oragenics, Inc. (OGEN)?
What is the 5-year average PE Ratio for Oragenics, Inc. (OGEN)?
How does the current PE Ratio for Oragenics, Inc. (OGEN) compare to its historical average?